ALC vs BLCO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALC and BLCO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALC and BLCO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alcon makes the things an ophthalmologist and an optometrist use every day. The Surgical division sells cataract equipment (the Unity VCS and CS platforms, LenSx femtosecond lasers, the ARGOS biometer, NGENUITY 3D visualization, the Constellation vitreoretinal system) plus the intraocular lenses that get implanted during those procedures, including the PanOptix and Vivity presbyopia-correcting families and the newer Clareon TruPlus monofocal and toric lenses. The Vision Care division sells contact lenses (Precision1, Precision7, Dailies Total1, Total30) and ocular health products (Systane dry eye drops, allergy and lens care lines, and the recently launched Tryptyr dry eye drug). In the first quarter of 2026 the split was roughly $1.5 billion Surgical and $1.2 billion Vision Care on $2.7 billion of total sales, so Surgical is the larger side but not overwhelmingly so. The company is headquartered in Geneva, employs about 26,000 people, traces its roots to a 1945 Fort Worth pharmacy, and has been independent since Novartis spun it off in April 2019. It passed 175 million cumulative IOL implants in March 2026.

Full ALC guide

Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and lens-care solutions plus consumer eye drops such as LUMIFY and PreserVision supplements), Pharmaceuticals (around 25%, led by the dry-eye drug MIEBO and international brands), and Surgical (about 18%, including intraocular lenses, phacoemulsification systems and cataract and retina instruments). Full-year 2025 revenue reached roughly $5.1 billion, trailing twelve-month revenue is now about $5.3 billion, and the company sells into the structurally growing markets of an aging population, rising myopia and expanding cataract volumes.

Full BLCO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALC drivers: Demographics that do not switch off; An unusually dense 2026 product cycle.
• BLCO drivers: Margin and EBITDA expansion; Pharmaceuticals and MIEBO ramp.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The immediate risk is that soft cataract and premium-lens volumes are not a 2026 phenomenon, in which case a 5% to 7% constant currency growth guide gets revised down again after multiple cuts already in 2025 and 2026. For BLCO, the dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALC if you believe its drivers more; BLCO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALC and BLCO guides.

ALC. The two P/E figures tell the whole disagreement. Trailing GAAP earnings are depressed by amortization from the Novartis separation and by the cost of running several product launches at once, which is why the stock screens at roughly 50 times trailing and roughly 17 times forward. Gross margin sits near 57% and cash generation is steady, so the question is not whether the business generates cash, it is whether the 2026 margin expansion guide of 70 to 170 basis points holds through the November 10, 2026 report. Shares trade near the bottom of a ~$61.83 to ~$87.64 52-week range against an average analyst target around $83.

BLCO. BLCO is not yet GAAP-profitable, so investors lean on adjusted EBITDA, forward earnings and revenue growth rather than trailing multiples. At about 13 times EV/EBITDA, 15 times forward earnings and roughly 1.1 times sales, the stock trades below eye-care peers such as Alcon and The Cooper Companies, a gap that reflects the Bausch Health control discount, leverage and now a leadership transition. Q3 2026 results are due October 28, 2026, with consensus at about $1.37 billion of revenue and $0.22 of adjusted EPS, and the company has already signaled a guidance raise.

Headline figures (approximate, October 2026): ALC shows revenue (ttm) ~$10.9 billion, up ~8.7% year over year in Q2 2026, q2 2026 sales ~$2.82 billion; core diluted EPS $0.84 vs $0.76 expected, margins (ttm) ~57% gross, ~15% operating, ~6% net, earnings per share ~$1.32 trailing GAAP; ~$3.50 core expected for 2026; BLCO shows revenue (ttm) ~$5.3B, revenue growth (q2 2026, yoy) ~9%, q2 2026 revenue ~$1.39B (adj. EPS $0.16 vs $0.16 est.), gross / operating margin ~61% / ~8%.

ALC and BLCO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALC and BLCO exposure against your real portfolio. It is not an investment adviser.